CYCLERION THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
CYCLERION THERAPEUTICS, INC. (CYCN) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$3.06 million for the 12-month period ending 2024-12-31, per its 10-K/A filed 2025-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-11-12
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was $530.00K.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$723.00K.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$1.32M.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$1.54M.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$3.06M.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$12.59M.
- CYCLERION THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$18.25M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-12-31 | $530.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | -$193.00K derived: sum of 2 quarters · filed 2025-11-12 | -$1.51M derived: sum of 3 quarters · filed 2025-11-12 | -$3.06M 10-K/A · filed 2025-11-12 |
| 2024-09-30 | -$723.00K 10-Q · filed 2024-11-14 | -$2.04M derived: sum of 2 quarters · filed 2024-11-14 | -$3.59M 10-Q · filed 2024-11-14 | -$5.28M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.32M 10-Q · filed 2024-08-07 | -$2.86M 10-Q · filed 2024-08-07 | -$4.56M derived: sum of 3 quarters · filed 2025-11-12 | -$10.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$1.54M 10-Q · filed 2024-05-07 | -$3.24M derived: sum of 2 quarters · filed 2025-11-12 | -$9.14M derived: sum of 3 quarters · filed 2025-11-12 | -$10.95M derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | -$1.69M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | -$7.60M derived: sum of 2 quarters · filed 2025-11-12 | -$9.40M derived: sum of 3 quarters · filed 2025-11-12 | -$12.59M 10-K/A · filed 2025-11-12 |
| 2023-09-30 | -$5.91M 10-Q · filed 2024-11-14 | -$7.71M derived: sum of 2 quarters · filed 2024-11-14 | -$10.90M 10-Q · filed 2024-11-14 | -$15.22M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$1.80M 10-Q · filed 2024-08-07 | -$4.99M 10-Q · filed 2024-08-07 | -$9.31M derived: sum of 3 quarters · filed 2024-08-07 | -$13.72M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$3.19M 10-Q · filed 2024-05-07 | -$7.51M derived: sum of 2 quarters · filed 2024-05-07 | -$11.92M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2022-12-31 | -$4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$8.73M derived: sum of 2 quarters · filed 2024-03-05 | -$18.25M 10-K · filed 2024-03-05 | |
| 2022-09-30 | -$4.41M 10-Q · filed 2023-11-13 | -$13.92M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |